According to information released by the group, the distribution campaign for maternity wards is scheduled to commence on September 15 across mainland France. Treatment will be accessible in pharmacies starting from week 35 (August 26 – September 1), with administration by a doctor.
Sanofi’s Beyfortus, akin to a vaccine, underwent extensive testing last winter in various countries, including France. Studies have shown that Beyfortus effectively reduced hospitalizations among infants, marking a positive outcome for its effectiveness.
Available from September to January, Beyfortus and Pfizer’s Abrysvo vaccine, recommended by the High Authority for Health (HAS), offer options for parents seeking to immunize their infants against respiratory syncytial virus (RSV), the primary cause of bronchiolitis. The HAS endorsement includes a recommendation for these products to be offered to parents during the critical period from September through January.